These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10522426)

  • 1. [Lipodystrophy and antiretroviral agents].
    Martínez E; Gatell JM
    Rev Clin Esp; 1999 Aug; 199(8):485-6. PubMed ID: 10522426
    [No Abstract]   [Full Text] [Related]  

  • 2. A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
    Hanna L
    BETA; 1998 Oct; ():9-13. PubMed ID: 11365999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cushing's syndrome mimicking lipodystrophy syndrome in a patient with AIDS.
    Bates SM; Page KB; Nakielny RA; Talbot MD
    Int J STD AIDS; 2002 Sep; 13(9):648-9. PubMed ID: 12243135
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antiretroviral therapy. NNRTI (non-nucleoside reverse transcriptase inhibitor)].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():14-6. PubMed ID: 10863304
    [No Abstract]   [Full Text] [Related]  

  • 5. [Protease inhibitor saving alternatives].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():16-7. PubMed ID: 10863305
    [No Abstract]   [Full Text] [Related]  

  • 6. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
    N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical update: new drugs for HIV/AIDS.
    Gracia Jones S; Baggett TH
    Medsurg Nurs; 1999 Apr; 8(2):108-12. PubMed ID: 10410008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-nucleoside reverse transcriptase inhibitor as a fully viable alternative. Strong therapy start without protease inhibitor].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():30-3. PubMed ID: 10863307
    [No Abstract]   [Full Text] [Related]  

  • 9. NNRTI choice: has 2NN changed our practice?
    Moyle GJ
    AIDS Read; 2003 Jul; 13(7):325-8. PubMed ID: 12889450
    [No Abstract]   [Full Text] [Related]  

  • 10. Perspectives on HAART: switch maintenance therapy.
    Leen CL
    Int J STD AIDS; 2003 Sep; 14(9):577-82. PubMed ID: 14511491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children.
    Rosso R; Di Biagio A; Dentone C; Bassetti M; Viscoli C; Parodi A; De Maria A
    Int J Antimicrob Agents; 2007 Feb; 29(2):228-30. PubMed ID: 17196369
    [No Abstract]   [Full Text] [Related]  

  • 13. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
    Meyer-Kleinmann J
    Infection; 2004 Jun; 32(3):7. PubMed ID: 15230276
    [No Abstract]   [Full Text] [Related]  

  • 15. Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution.
    Moyle G; Baldwin C
    AIDS Read; 2000 Aug; 10(8):479-85. PubMed ID: 10967808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of NNRTIs in antiretroviral-experienced patients.
    Maggiolo F
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():10-7. PubMed ID: 11589823
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
    Brinkman K; Smeitink JA; Romijn JA; Reiss P
    Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-nucleoside reverse transcriptase inhibitors--an overview.
    Bell C; Matthews GV; Nelson MR
    Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.